Bempedoic Acid Study 1 Results Published in The New England Journal of Medicine Demonstrates Significant LDL-Cholesterol Lowering and Reduced Marker of Underlying Cardiovascular Inflammation, with...

  • Bempedoic acid is an oral, once-daily ATP Citrate Lyase (ACL) Inhibitor that reduces cholesterol and fatty acid synthesis in the liver
  • Study 1 is the largest of a comprehensive five Phase 3 study programme investigating the benefits of bempedoic acid in patients requiring......
    . .
    Veröffentlicht von: Finanzen.at - Nachrichten Ticker - 4 days ago
Share |